Gosgon (Goserelin)

Gosgon (goserelin) is prescribed for a range of hormone‑sensitive conditions where suppression of sex hormone production is desired, typically administered as a monthly or quarterly subcutaneous injection under medical supervision.

• Prostate cancer in men, usually as part of combined androgen deprivation therapy.
• Hormone‑receptor positive breast cancer in pre‑menopausal women, often combined with ovarian suppression.
• Endometriosis associated with pelvic pain and lesion growth.
• Symptomatic uterine fibroids requiring medical management.
• Central precocious puberty to delay early sexual development.
• Occasionally used off‑label for other GnRH‑dependent disorders under specialist supervision.

The pharmacologic activity of goserelin can produce a range of adverse effects, most of which are related to reduced sex hormone levels.

Common

• Hot flashes or night sweats.
• Decreased libido or erectile dysfunction in men.
• Menstrual irregularities or amenorrhea in women.
• Injection site reactions such as redness, swelling, or mild pain.
• Mood changes including mild depression or anxiety.
• Bone mineral density loss with long‑term use.
• Fatigue or general weakness.

Serious

• Cardiovascular events such as myocardial infarction or stroke, especially in patients with pre‑existing risk factors.
• Severe osteoporosis leading to fractures.
• Acute allergic reactions, including anaphylaxis.
• Severe injection‑site infection or abscess formation.
• Severe liver enzyme elevation.

Before initiating therapy with Gosgon, clinicians should evaluate patient history and monitor for conditions that may be aggravated by profound hormone suppression.

• Assess cardiovascular risk; GnRH agonists may raise thromboembolic risk.
• Evaluate bone health; baseline densitometry is advised for osteoporosis risk.
• Review liver function; severe hepatic impairment can alter metabolism.
• Monitor glucose control, especially in diabetic patients.
• Discuss fertility; gonadal suppression may be reversible after stopping therapy.
• Observe mood changes such as depression or anxiety.
• Use proper subcutaneous technique to limit injection‑site reactions.

Gosgon may interact with other medicines that influence hormone pathways, cardiovascular health, or metabolic processes.

Avoid

• Combined use with other GnRH agonists or antagonists, which can cause excessive hormone suppression.
• Concomitant administration of potent CYP3A4 inducers that may reduce goserelin exposure (e.g., rifampin, carbamazepine).

Use with caution

• Anticoagulants, because altered hormone levels can affect coagulation parameters.
• Antidiabetic agents, as changes in glucose metabolism may require dose adjustment.
• Bisphosphonates or denosumab, when used to protect bone density during long‑term therapy.
• Hormonal contraceptives, which may be less effective during GnRH agonist treatment.